H.C. Wainwright Thinks Celyad’s Stock is Going to Recover

H.C. Wainwright analyst Edward White maintained a Buy rating on Celyad (CYADResearch Report) today and set a price target of $13.00. The company’s shares closed last Thursday at $4.19, close to its 52-week low of $3.53.

According to, White is a 4-star analyst with an average return of 7.8% and a 36.8% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Silverback Therapeutics, and Karyopharm Therapeutics.

Celyad has an analyst consensus of Moderate Buy.

See Insiders’ Hot Stocks on TipRanks >>

Celyad’s market cap is currently $92.64M and has a P/E ratio of -3.30. The company has a Price to Book ratio of 4.55.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Celyad SA is a clinical-stage biopharmaceutical company, which engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno-oncology, and Corporate. The Cardiology segment includes the company’s Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

Read More on CYAD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More